Temporal and Spatial Variability of Micropollutants in a Brazilian Urban River.

In Brazil, environmental occurrence of micropollutants, such as pharmaceuticals, is rarely studied, and these compounds are not part of national water quality guidelines. In this study, we evaluated the occurrence of micropollutants in the Paraibuna River, located in the southeast region of Brazil, which is the most populated region of the country. Surface water samples were taken every 3 months for 1.5 years at four different sites downstream the city of Juiz de Fora. A total of 28 compounds were analyzed on an UHPLC-Orbitrap-MS/MS using a direct injection method. Nine substances were found in at least one water sample, with concentrations ranging from 11 to 4471 ng L-1. The micropollutants found in the river were not detected at the reference site upstream of the city, except for caffeine, which was present at low concentrations in the reference site. Additionally, a nontarget screening of the river samples was applied, which resulted in the identification of 116 chemicals, most of which were pharmaceuticals. Concentrations of most of the micropollutants varied with season and correlated significantly with rainfall events, which caused dilution in the river. The highest observed concentrations were for pharmaceuticals used for treating chronic diseases, such as metformin, which is used to treat diabetes, and were among the most consumed in Juiz de Fora during the study period. Moderate ecotoxicological risks were found for metformin, oxazepam, triclosan, and tramadol. Considering the complex mixture of micropollutants in the environment, more knowledge is needed to elucidate their ecological risk in aquatic ecosystems.

Hematological change parameters in patients with pressure ulcer at long-term care hospital.

OBJECTIVE: To assess factors associated with the development of pressure ulcers, and to compare the effectiveness of pharmacological treatments. METHODS: The factors associated with the development of pressure ulcers were compared in lesion-carrying patients (n=14) and non-carriers (n=16). Lesion-carrying patients were treated with 1% silver sulfadiazine or 0.6IU/g collagenase and were observed for 8 weeks. The data collected was analyzed with p<0.05 being statistically relevant. RESULTS: The prevalence of pressure ulcers was about 6%. The comparison of carrier and non-carrier groups of pressure ulcers revealed no statistically significant difference in its occurrence with respect to age, sex, skin color, mobility, or the use of diapers. However, levels of hemoglobin, hematocrit, and red blood cells were found to be statistically different between groups, being lower in lesion-carrying patients. There was no significant difference found in lesion area between patients treated with collagenase or silver sulfadiazine, although both groups showed an overall reduction in lesion area through the treatment course. CONCLUSION: Hematologic parameters showed a statistically significant difference between the two groups. Regarding the treatment of ulcers, there was no difference in the area of the lesion found between the groups treated with collagenase and silver sulfadiazine.

Hematological change parameters in patients with pressure ulcer at long-term care hospital / Alterações dos parâmetros hematológicos em pacientes portadores de úlcera por pressão em um hospital de longa permanência

Objective To assess factors associated with the development of pressure ulcers, and to compare the effectiveness of pharmacological treatments. Methods The factors associated with the development of pressure ulcers were compared in lesion-carrying patients (n=14) and non-carriers (n=16). Lesion-carrying patients were treated with 1% silver sulfadiazine or 0.6IU/g collagenase and were observed for 8 weeks. The data collected was analyzed with p<0.05 being statistically relevant. Results The prevalence of pressure ulcers was about 6%. The comparison of carrier and non-carrier groups of pressure ulcers revealed no statistically significant difference in its occurrence with respect to age, sex, skin color, mobility, or the use of diapers. However, levels of hemoglobin, hematocrit, and red blood cells were found to be statistically different between groups, being lower in lesion-carrying patients. There was no significant difference found in lesion area between patients treated with collagenase or silver sulfadiazine, although both groups showed an overall reduction in lesion area through the treatment course. Conclusion Hematologic parameters showed a statistically significant difference between the two groups. Regarding the treatment of ulcers, there was no difference in the area of the lesion found between the groups treated with collagenase and silver sulfadiazine. .

Objetivo Avaliar os fatores associados ao desenvolvimento da úlcera por pressão e comparar a efetividade de tratamentos farmacológicos. Métodos Os fatores associados ao desenvolvimento de úlcera por pressão foram comparados entre pacientes portadores (n=14) e não portadores (n=16) da lesão. Os pacientes com a ferida foram tratados com sulfadiazina de prata 1% ou colagenase 0,6UI/g, sendo acompanhados durante 8 semanas. Os dados coletados foram analisados considerando-se estatisticamente significativo se p<0,05. Resultados A prevalência de úlcera por pressão foi de cerca de 6%. A comparação entre os grupos de portadores e não portadores de úlcera por pressão não revelou diferença estatística significativa entre ocorrência desta segundo idade, sexo, cor da pele, mobilidade e uso de fralda. Por outro lado, os valores de hemoglobina, hematócrito e hemácias foram estatisticamente diferentes entre os grupos, sendo menor naqueles pacientes portadores da lesão. Não houve diferença significativa na área da lesão entre aqueles pacientes tratados com colagenase ou sulfadiazina de prata, embora ambos os tratamentos tenham evidenciado uma redução média da área da lesão. Conclusão Os parâmetros hematológicos apresentaram diferença estatística entre os dois grupos avaliados, ao contrário das demais variáveis analisadas. Em relação ao tratamento das úlceras, não houve diferença na área da lesão na comparação entre a colagenase e a sulfadiazina. .

Effects of angiotensin-converting enzyme inhibition on leptin and adiponectin levels in essential hypertension.

Activation of the renin-angiotensin-aldosterone system (RAAS) and abnormal adipokine levels are biological alterations that affect blood pressure regulation and interact to link hypertension, obesity and metabolic diseases. While imbalanced levels of hormones produced by adipocytes including hypo-adiponectinaemia and hyperleptinaemia were reported in hypertension, little is known about how antihypertensive therapy affects these alterations. This study aimed to evaluate the effects of enalapril on plasma adiponectin and leptin levels in hypertensive individuals. Thirty-seven untreated hypertensive patients were prospectively treated with enalapril for 8 weeks. Blood samples were collected at baseline and after the treatment with enalapril. Plasma adiponectin and leptin levels were measured by enzyme-linked immunoassay. We found significant increases in adiponectin levels after enalapril treatment (5.4 ± 3.7 versus 6.0 ± 4.5 µg/mL, mean ± S.D., p = 0.04). Conversely, leptin levels were unchanged (18.0 ± 14.7 versus 18.4 ± 14.8 ng/mL, mean ± S.D., p = 0.31). Multiple linear regression revealed that baseline leptin is a significant predictor of systolic blood pressure reduction (ß=0.269, p = 0.01) in hypertensive individuals treated with enalapril. While enalapril increases adiponectin levels in hypertensive individuals, baseline leptin levels predict blood pressure reduction in response to this therapy. These findings support the idea of an important relationship between RAAS and adipose tissue in hypertension and suggest that enalapril improves the adipokine profile, possibly allowing beneficial effects to overweight or obese hypertensive individuals.

Stachytarpheta gesnerioides Cham: chemical composition of hexane fraction and essential oil, antioxidant and antimicrobial activities / Stachytarpheta gesnerioides Cham: composición química de la fracción hexánica y aceite esencial, actividades antioxidante y antimicrobiana

In the present study we investigated the chemical composition of hexane fraction and essential oil of Stachytarpheta gesnerioides (Verbenaceae) by GC-MS, total phenol and flavonoid contents. The antioxidant capacity and antimicrobial activity were investigated in five extracts of leaves of S. gesnerioides. Aqueous and 100 percent ethanol extracts were prepared by dynamic maceration. Hexane, ethyl acetate and methanol extracts were prepared by Soxhlet extraction. The essential oil (EO) and hexane fraction (HF) are mainly composed by guaiol. Moreover, the HF is also rich in the monoterpene alpha-pinene. The total phenol content ranged from 0.85 to 22.74 mg gallic acid equivalent /100mg dry extract at Folin–Ciocalteu’s reagent method. The total flavonoid concentration ranged from 0.68 to 13.65 mg rutin equivalent /100mg dry extract, detected using 8 percent aluminium chloride. The ethyl acetate extract (IC50=9.41 ug/ml) showed the highest antioxidant activity. The extracts were found to be effective to inhibit the microorganisms tested.

Se han investigado la composición química de la fracción hexánica (FH) y aceite esencial (AE) de Stachytarpheta gesnerioides (Verbenaceae) por GC-MS, el contenido de fenoles totales y flavonoides. La capacidad antioxidante y actividad antimicrobiana fueron investigadas en cinco extractos de hojas de S gesnerioides. Extractos acuosos y etanolico fueron preparados por la maceración dinámica y extracción continua en Soxhlet con hexano, acetato de etilo y metanol. Las fracciones AE y FH están compuestas principalmente por guaiol. La fracción FH es también rica en alfa-pineno. El contenido de fenoles totales varió desde 0,85 hasta 22,74 mg de ácido gálico/100 mg de extracto seco (Folin-Ciocalteu). La concentración total de flavonoides varió desde 0,68 hasta 13,65 mg en equivalentes de rutina/100 mg de extracto seco, que se detectó mediante reacción con cloruro de aluminio al 8 por ciento. El extracto de acetato de etilo (CI50=9,41 ug/ml) enseño la más grande actividad antioxidante. Los extractos se encontraron eficaces para inhibir los microorganismos ensayados.

Pharmacogenetic implications of the eNOS polymorphisms for cardiovascular action drugs.

The pharmacogenetics is one of the most promising fields of medicine. The conclusion of the Genome Project allowed this field to start discovering complex factors modulating the response to drugs, and new technologies are close a great expansion of the area. The cardiovascular diseases are currently among the major causes of hospitalizations and death, and have been the target of a large part of genetic studies of complex diseases. Parallel to the susceptibility to disease markers identification, it is necessary to investigate how different genetic profiles can change the responses to the currently used drugs. The biological system that controls the endothelial production of the nitric oxide has been one of the greatest targets in the pharmacological responses to the drugs used in the cardiovascular diseases therapy. This review aims at approaching the current knowledge on interaction among the genetic variations of eNOS and the pharmacological responses to the drugs used in the cardiovascular system.

Implicações farmacogenéticas de polimorfismos da eNOS para drogas de ação cardiovascular / Pharmacogenetic implications of the eNOS polymorphisms for cardiovascular action drugs / Implicaciones farmacogenéticas de polimorfismos de la eNOS para drogas de acción cardiovascular

A farmacogenética é um dos campos mais promissores da medicina. A conclusão do Projeto Genoma permitiu que esse campo começasse a descobrir fatores complexos modulando a resposta às drogas, e novas tecnologias estão a poucos passos de permitir uma grande expansão da área. As doenças cardiovasculares estão atualmente entre as maiores causas de internações hospitalares e morte, e têm sido alvo de grande parte dos estudos genéticos de doenças complexas. Paralelamente à identificação de marcadores de suscetibilidade à doença, é necessária a investigação de como perfis genéticos diferentes podem alterar respostas aos fármacos atualmente empregados. O sistema biológico que controla a produção endotelial do óxido nítrico tem sido um dos grandes alvos nas respostas farmacológicas aos fármacos usados na terapia de doenças cardiovasculares. Esta revisão tem como objetivo abordar os conhecimentos correntes da interação entre as variações genéticas da eNOS e as respostas farmacológicas aos fármacos empregados no sistema cardiovascular.

The pharmacogenetics is one of the most promising fields of medicine. The conclusion of the Genome Project allowed this field to start discovering complex factors modulating the response to drugs, and new technologies are close a great expansion of the area. The cardiovascular diseases are currently among the major causes of hospitalizations and death, and have been the target of a large part of genetic studies of complex diseases. Parallel to the susceptibility to disease markers identification, it is necessary to investigate how different genetic profiles can change the responses to the currently used drugs. The biological system that controls the endothelial production of the nitric oxide has been one of the greatest targets in the pharmacological responses to the drugs used in the cardiovascular diseases therapy. This review aims at approaching the current knowledge on interaction among the genetic variations of eNOS and the pharmacological responses to the drugs used in the cardiovascular system.

La farmacogenética es uno de los campos más promisorios de la medicina. La conclusión del Proyecto Genoma permitió que ese campo comenzase a descubrir factores complejos modulando la respuesta a las drogas, y nuevas tecnologías están a pocos pasos de permitir una gran expansión del área. Las enfermedades cardiovasculares están actualmente entre las mayores causas de internaciones hospitalarias y muerte, y han sido objeto de gran parte de los estudios genéticos de enfermedades complejas. Paralelamente a la identificación de marcadores de susceptibilidad a la enfermedad, es necesaria la investigación sobre como perfiles genéticos diferentes pueden alterar respuestas a los fármacos actualmente empleados. El sistema biológico que controla la producción endotelial del óxido nítrico ha sido un de los grandes blancos en las respuestas farmacológicas a los fármacos usados en la terapia de enfermedades cardiovasculares. Esta revisión tiene como objetivo abordar los conocimientos corrientes de la interacción entre las variaciones genéticas de la eNOS y las respuestas farmacológicas a los fármacos empleados en el sistema cardiovascular.